SEOUL, Jan. 13 (Korea Bizwire) — Samsung Biologics, a major South Korean contract drug manufacturer, said Thursday it plans to start building a fifth plant this year to meet rising orders. The company’s fourth plant, currently under construction, is set to be partially operational from October starting with a bioreactor capacity of 60,000 liters, CEO [...]
SEOUL, Aug. 11 (Korea Bizwire) — Samsung Biologics, a biopharmaceutical unit of South Korea’s largest conglomerate Samsung Group, said Tuesday that it will build a fourth plant in the country in response to rising manufacturing demand. The 1.7 trillion-won (US$1.4 billion) plant in Songdo, western Incheon, will have a bioreactor capacity of 256,000 liters, the [...]
SEOUL, Jan. 21 (Korea Bizwire) — Major South Korean biosimilar manufacturer Celltrion Inc. said Tuesday it will spend 600 billion won (US$520 million) on its new plant in China over the next five years. The planned plant, with a production capacity of 120,000 liters of biopharmaceutical products, will be located in the central city of [...]